These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23182909)

  • 1. Characterization of a type O foot-and-mouth disease virus re-emerging in the year 2011 in free areas of the Southern Cone of South America and cross-protection studies with the vaccine strain in use in the region.
    Maradei E; Malirat V; Beascoechea CP; Benitez EO; Pedemonte A; Seki C; Novo SG; Balette CI; D'Aloia R; La Torre JL; Mattion N; Toledo JR; Bergmann IE
    Vet Microbiol; 2013 Mar; 162(2-4):479-490. PubMed ID: 23182909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of foot-and-mouth disease virus from outbreaks in Ecuador during 2009-2010 and cross-protection studies with the vaccine strain in use in the region.
    Maradei E; Perez Beascoechea C; Malirat V; Salgado G; Seki C; Pedemonte A; Bonastre P; D'Aloia R; La Torre JL; Mattion N; Rodríguez Toledo J; Bergmann IE
    Vaccine; 2011 Oct; 29(46):8230-40. PubMed ID: 21911020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SAT2 foot-and-mouth disease 2013/2014 outbreak viruses at the wildlife-livestock interface in South Africa.
    Blignaut B; van Heerden J; Reininghaus B; Fosgate GT; Heath L
    Transbound Emerg Dis; 2020 Jul; 67(4):1595-1606. PubMed ID: 31984622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a high quality O
    Galdo Novo S; Malirat V; Maradei ED; Pedemonte AR; Espinoza AM; Smitsaart E; Lee KN; Park JH; Bergmann IE
    Vaccine; 2018 Mar; 36(12):1570-1576. PubMed ID: 29472132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring the performance of foot-and-mouth disease vaccines prepared against local strains in the face of antigenic evolution in the field.
    Tuncer-Göktuna P; Çokçalışkan C; Arslan A; Taşçene N; Uzun EA; Gündüzalp C; Balcı GN; Kara O; Gülyaz V
    Transbound Emerg Dis; 2021 Mar; 68(2):648-655. PubMed ID: 32677765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Vaccine Based on the A/ASIA/G-VII Lineage of Foot-and-Mouth Disease Virus Offers Low Levels of Protection against Circulating Viruses from the A/ASIA/Iran-05 lineage.
    Singanallur NB; Eblé PL; Ludi AB; Statham B; Bin-Tarif A; King DP; Dekker A; Vosloo W
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen.
    Nagendrakumar SB; Srinivasan VA; Madhanmohan M; Yuvaraj S; Parida S; Di Nardo A; Horsington J; Paton DJ
    Vaccine; 2011 Feb; 29(10):1906-12. PubMed ID: 21236232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in foot-and-mouth disease virus strain selection as an input to attain broad vaccine intraserotype cross-protection.
    Bergmann IE; Malirat V; Pedemonte A; Maradei E
    Expert Rev Vaccines; 2021 Jan; 20(1):13-22. PubMed ID: 33455492
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemiological analysis of an outbreak of foot-and-mouth disease (serotype SAT2) on a large dairy farm in Kenya using regular vaccination.
    Lyons NA; Stärk KD; van Maanen C; Thomas SL; Chepkwony EC; Sangula AK; Dulu TD; Fine PE
    Acta Trop; 2015 Mar; 143():103-11. PubMed ID: 25447264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic and immunogenic spectrum of foot-and-mouth disease vaccine strain O
    Galdo Novo S; Malirat V; Maradei ED; Espinoza AM; Smitsaart E; Pedemonte AR; Mattion N; Bergmann IE
    Vaccine; 2017 Apr; 35(18):2303-2307. PubMed ID: 28343779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phylogenetic analysis of foot-and-mouth disease virus type O re-emerging in free areas of South America.
    Malirat V; de Barros JJ; Bergmann IE; Campos Rde M; Neitzert E; da Costa EV; da Silva EE; Falczuk AJ; Pinheiro DS; de Vergara N; Cirvera JL; Maradei E; Di Landro R
    Virus Res; 2007 Mar; 124(1-2):22-8. PubMed ID: 17056146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease.
    Mattion N; König G; Seki C; Smitsaart E; Maradei E; Robiolo B; Duffy S; León E; Piccone M; Sadir A; Bottini R; Cosentino B; Falczuk A; Maresca R; Periolo O; Bellinzoni R; Espinoza A; Torre JL; Palma EL
    Vaccine; 2004 Oct; 22(31-32):4149-62. PubMed ID: 15474705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a polyvalent foot-and-mouth disease virus vaccine containing A Saudi-95 against field challenge on large-scale dairy farms in Saudi Arabia with the emerging A/ASIA/G-VII viral lineage.
    Lyons NA; Ludi AB; Wilsden G; Hamblin P; Qasim IA; Gubbins S; King DP
    Vaccine; 2017 Dec; 35(49 Pt B):6850-6857. PubMed ID: 29108665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The field effectiveness of routine and emergency vaccination with an inactivated vaccine against foot and mouth disease.
    Elnekave E; Li Y; Zamir L; Even-Tov B; Hamblin P; Gelman B; Hammond J; Klement E
    Vaccine; 2013 Jan; 31(6):879-85. PubMed ID: 23246551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina.
    Maradei E; La Torre J; Robiolo B; Esteves J; Seki C; Pedemonte A; Iglesias M; D'Aloia R; Mattion N
    Vaccine; 2008 Dec; 26(51):6577-86. PubMed ID: 18835312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of high-potency FMDV O
    Horsington J; Perez CB; Maradei E; Novo SG; Gonzales JL; Singanallur NB; Bonastre P; Vosloo W
    Vaccine; 2017 Sep; 35(38):5179-5185. PubMed ID: 28789849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response.
    Golde WT; Pacheco JM; Duque H; Doel T; Penfold B; Ferman GS; Gregg DR; Rodriguez LL
    Vaccine; 2005 Dec; 23(50):5775-82. PubMed ID: 16153756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep.
    Singanallur NB; Pacheco JM; Arzt J; Stenfeldt C; Fosgate GT; Rodriguez L; Vosloo W
    Antiviral Res; 2017 Sep; 145():114-122. PubMed ID: 28780422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection induced by a commercial bivalent vaccine against Foot-and-Mouth Disease 2010 field virus from Ecuador.
    Duque H; Naranjo J; Carrillo C; Burbano A; Vargas J; Pauszek L; Olesen I; Sanchez-Vazquez MJ; Cosivi O; Allende RM
    Vaccine; 2016 Jul; 34(35):4140-4144. PubMed ID: 27395565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phylogenetic analysis of Foot-and-Mouth Disease Virus type O circulating in the Andean region of South America during 2002-2008.
    Malirat V; Bergmann IE; Campos Rde M; Salgado G; Sánchez C; Conde F; Quiroga JL; Ortiz S
    Vet Microbiol; 2011 Aug; 152(1-2):74-87. PubMed ID: 21601999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.